Symptoms and signs at outpatient review
| Symptom | Group |
Start of trial (%) |
6 weeks (%) |
16 weeks (%) | |
| Pain | GTN | 20/20 (100.0) | 13/17 (76.4) | 6/13 (46.1) | |
| Placebo | 20/20 (100.0) | 9/17 (52.9) | 4/16 (25.0) | ||
| Bleeding | GTN | 17/20 (85.0) | 5/16 (31.2) | 2/11 (18.1) | |
| Placebo | 15/20 (75.0) | 4/17 (23.5) | 2/15 (13.3) | ||
| Constipation | GTN | 17/20 (85.0) | 8/17 (47.1) | 4/11 (36.3) | |
| Placebo | 17/20 (85.0) | 4/11 (36.4) | 3/14 (21.4) | ||
| Visible fissure | GTN | 20/20 (100.0) | 7/15 (46.6) | 3/11 (27.2) | |
| Placebo | 20/20 (100.0) | 4/16 (25.0) | 1/15 (6.7) | ||
| Visible skin tags | GTN | 8/20 (40.0) | 6/15 (40.0) | 3/10 (30.0) | |
| Placebo | 7/20 (35.0) | 4/16 (25.0) | 4/15 (26.7) | ||
| Faecal loading | GTN | 7/20 (35.0) | 4/15 (26.7) | 1/10 (10.0) | |
| Placebo | 6/20 (30.0) | 2/16 (12.5) | 4/15 (26.7) | ||